Special Issue

Histiocytosis and Treatment Targets

Message from the Guest Editor

Histiocytosis encompasses intriguing rare blood cancer disorders characterized by the accumulation of tissue histocytes, often accompanied by inflammatory infiltrates. Histiocytosis is considered a clonal disorder with a high frequency of somatic mutations resulting in activation of the MEK–ERK signaling pathway. Recent breakthroughs in understanding the mitogen-activated protein kinase (MAPK) pathway have identified therapeutic strategies with targeted therapies for this pathway. However, the disease can still be difficult to manage in terms of efficacy for MAPK pathway targets in individual patients. We invite authors to explore the intricate interplay between histiocytosis and pharmacology, with a focus on Langerhans cell histiocytosis, Erdheim–Chester disease and juvenile xanthogranuloma. The topics of interest may include, but are not limited to, gene pathway analysis of targeted therapy, health system models of therapeutic access to targeted therapy, complexity of RAS mutations as druggable targets, toxicity with targeted therapy, “drug holidays” and resistance. Join us in unravelling the mysteries of therapeutic targets and outcomes in histiocytosis.

Guest Editor

Prof. Dr. Craig Steven McLachlan
Centre for Healthy Futures, Torrens University Australia, Pyrmont, NSW 2009, Australia

Deadline for manuscript submissions

closed (30 November 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/203413

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).